Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the past few years, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNAs, autoantibodies, and T-cell receptor repertoire are new biomarkers of liquid biopsy in cancer, which has been demonstrated to have a great value in diagnostics, treatment evaluation, and prognosis prediction. However, most of previous data were based on late stage tumor patients. This study plans to utilize the minimally invasive method to detect the changes of numbers of CTCs, ctDNA hot spot mutations and methylation signals, microRNAs, autoantibodies, and T-cell receptor repertoire in early stage lung cancer patients before and after pulmonary nodule biopsy, during therapeutic and follow-up periods, in order to evaluate the clinical values of above tumor-related biomarkers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer

NCT04156360

Healthy Pulmonary Nodule

UNKNOWN

Early Adjuvant Diagnosis of Pulmonary Nodules Based on CTC.

NCT06187935

Pulmonary Nodules, Solitary Pulmonary Nodules, Multiple

COMPLETED

To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer

NCT05432128

Lung Cancer

RECRUITING

Identify Prognostic Biomarkers of Lung Cancer

NCT05010330

Lung Cancer Lung Adenocarcinoma Lung Squamous Cell Carcinoma +1 more

UNKNOWN

Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

NCT05965557

Lung Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed as suspected lung cancer patients with pulmonary nodules (single or multiple) by CT scans, and the maximum diameter of nodule is between 8mm and 3cm;
* Male or female, with age of 18\~80 years;
* Agree to take the pulmonary nodule biopsy, and sign the Informed Consent.

Exclusion Criteria

* With severe comorbidities and unable to participate in this study;
* Diagnosed with acute respiratory tract infection, for instance fungus, mycobacterium tuberculosis or other bacteria, virus, etc., one month prior to the study recruitment;
* Pregnant or maternal women;
* Diagnosed with other carcinoma, and the pulmonary nodules suspected of stemming from other sites;
* Unable for regular follow-ups according to the research protocol;
* Blood sample is not qualified for biomarker testing.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No